nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP2D6—Tamoxifen—pancreatic cancer	0.122	0.203	CbGbCtD
Vilazodone—CYP2D6—Erlotinib—pancreatic cancer	0.104	0.173	CbGbCtD
Vilazodone—CYP3A4—Tamoxifen—pancreatic cancer	0.0776	0.129	CbGbCtD
Vilazodone—CYP3A4—Erlotinib—pancreatic cancer	0.066	0.11	CbGbCtD
Vilazodone—CYP3A4—Irinotecan—pancreatic cancer	0.0596	0.0993	CbGbCtD
Vilazodone—CYP2D6—Doxorubicin—pancreatic cancer	0.0512	0.0853	CbGbCtD
Vilazodone—CYP3A4—Docetaxel—pancreatic cancer	0.0437	0.0728	CbGbCtD
Vilazodone—CYP3A4—Sunitinib—pancreatic cancer	0.0435	0.0725	CbGbCtD
Vilazodone—CYP3A4—Doxorubicin—pancreatic cancer	0.0326	0.0543	CbGbCtD
Vilazodone—Night sweats—Tamoxifen—pancreatic cancer	0.0123	0.0348	CcSEcCtD
Vilazodone—Cataract—Tamoxifen—pancreatic cancer	0.00698	0.0197	CcSEcCtD
Vilazodone—Dry eye—Erlotinib—pancreatic cancer	0.00607	0.0171	CcSEcCtD
Vilazodone—Hyponatraemia—Sunitinib—pancreatic cancer	0.00414	0.0117	CcSEcCtD
Vilazodone—Erectile dysfunction—Tamoxifen—pancreatic cancer	0.00384	0.0108	CcSEcCtD
Vilazodone—Hyponatraemia—Irinotecan—pancreatic cancer	0.00341	0.00965	CcSEcCtD
Vilazodone—Connective tissue disorder—Erlotinib—pancreatic cancer	0.00324	0.00916	CcSEcCtD
Vilazodone—Irritability—Fluorouracil—pancreatic cancer	0.00311	0.00879	CcSEcCtD
Vilazodone—Eye disorder—Erlotinib—pancreatic cancer	0.00308	0.00871	CcSEcCtD
Vilazodone—Mental disorder—Erlotinib—pancreatic cancer	0.00289	0.00817	CcSEcCtD
Vilazodone—Malnutrition—Erlotinib—pancreatic cancer	0.00287	0.00812	CcSEcCtD
Vilazodone—Dysgeusia—Tamoxifen—pancreatic cancer	0.00284	0.00803	CcSEcCtD
Vilazodone—Flatulence—Erlotinib—pancreatic cancer	0.00283	0.008	CcSEcCtD
Vilazodone—Connective tissue disorder—Sunitinib—pancreatic cancer	0.00281	0.00793	CcSEcCtD
Vilazodone—Eye disorder—Sunitinib—pancreatic cancer	0.00267	0.00754	CcSEcCtD
Vilazodone—Cardiac disorder—Sunitinib—pancreatic cancer	0.00265	0.00749	CcSEcCtD
Vilazodone—Mental disorder—Sunitinib—pancreatic cancer	0.0025	0.00707	CcSEcCtD
Vilazodone—Malnutrition—Sunitinib—pancreatic cancer	0.00249	0.00703	CcSEcCtD
Vilazodone—Arthralgia—Tamoxifen—pancreatic cancer	0.00247	0.00698	CcSEcCtD
Vilazodone—Flatulence—Sunitinib—pancreatic cancer	0.00245	0.00692	CcSEcCtD
Vilazodone—Arthralgia—Erlotinib—pancreatic cancer	0.00244	0.00691	CcSEcCtD
Vilazodone—Dysgeusia—Sunitinib—pancreatic cancer	0.00243	0.00688	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.00243	0.00686	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Epirubicin—pancreatic cancer	0.00242	0.00683	CcSEcCtD
Vilazodone—Dry mouth—Tamoxifen—pancreatic cancer	0.00242	0.00683	CcSEcCtD
Vilazodone—Hyponatraemia—Docetaxel—pancreatic cancer	0.00236	0.00667	CcSEcCtD
Vilazodone—Migraine—Docetaxel—pancreatic cancer	0.00231	0.00654	CcSEcCtD
Vilazodone—Connective tissue disorder—Irinotecan—pancreatic cancer	0.00231	0.00653	CcSEcCtD
Vilazodone—Nervous system disorder—Erlotinib—pancreatic cancer	0.0023	0.0065	CcSEcCtD
Vilazodone—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.00229	0.00647	CcSEcCtD
Vilazodone—Skin disorder—Erlotinib—pancreatic cancer	0.00228	0.00643	CcSEcCtD
Vilazodone—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.00225	0.00636	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Doxorubicin—pancreatic cancer	0.00224	0.00632	CcSEcCtD
Vilazodone—Cardiac disorder—Irinotecan—pancreatic cancer	0.00218	0.00617	CcSEcCtD
Vilazodone—Abnormal dreams—Epirubicin—pancreatic cancer	0.00216	0.0061	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.00216	0.0061	CcSEcCtD
Vilazodone—Convulsion—Sunitinib—pancreatic cancer	0.00215	0.00609	CcSEcCtD
Vilazodone—Insomnia—Tamoxifen—pancreatic cancer	0.00214	0.00606	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.00214	0.00604	CcSEcCtD
Vilazodone—Paraesthesia—Tamoxifen—pancreatic cancer	0.00213	0.00601	CcSEcCtD
Vilazodone—Cardiac disorder—Gemcitabine—pancreatic cancer	0.00213	0.00601	CcSEcCtD
Vilazodone—Breast disorder—Docetaxel—pancreatic cancer	0.00212	0.006	CcSEcCtD
Vilazodone—Insomnia—Erlotinib—pancreatic cancer	0.00212	0.00599	CcSEcCtD
Vilazodone—Arthralgia—Sunitinib—pancreatic cancer	0.00212	0.00598	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.0021	0.00594	CcSEcCtD
Vilazodone—Dyspepsia—Tamoxifen—pancreatic cancer	0.00209	0.00589	CcSEcCtD
Vilazodone—Dry mouth—Sunitinib—pancreatic cancer	0.00207	0.00585	CcSEcCtD
Vilazodone—Dyspepsia—Erlotinib—pancreatic cancer	0.00206	0.00583	CcSEcCtD
Vilazodone—Decreased appetite—Tamoxifen—pancreatic cancer	0.00206	0.00582	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00205	0.00578	CcSEcCtD
Vilazodone—Fatigue—Tamoxifen—pancreatic cancer	0.00204	0.00577	CcSEcCtD
Vilazodone—Decreased appetite—Erlotinib—pancreatic cancer	0.00204	0.00576	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00202	0.00572	CcSEcCtD
Vilazodone—Fatigue—Erlotinib—pancreatic cancer	0.00202	0.00571	CcSEcCtD
Vilazodone—Flatulence—Irinotecan—pancreatic cancer	0.00202	0.0057	CcSEcCtD
Vilazodone—Dry eye—Epirubicin—pancreatic cancer	0.00202	0.0057	CcSEcCtD
Vilazodone—Abnormal dreams—Doxorubicin—pancreatic cancer	0.002	0.00565	CcSEcCtD
Vilazodone—Nervous system disorder—Sunitinib—pancreatic cancer	0.00199	0.00562	CcSEcCtD
Vilazodone—Skin disorder—Sunitinib—pancreatic cancer	0.00197	0.00557	CcSEcCtD
Vilazodone—Dry eye—Doxorubicin—pancreatic cancer	0.00187	0.00528	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.00185	0.00522	CcSEcCtD
Vilazodone—Vision blurred—Fluorouracil—pancreatic cancer	0.00185	0.00522	CcSEcCtD
Vilazodone—Insomnia—Sunitinib—pancreatic cancer	0.00184	0.00519	CcSEcCtD
Vilazodone—Paraesthesia—Sunitinib—pancreatic cancer	0.00182	0.00515	CcSEcCtD
Vilazodone—Dyspepsia—Sunitinib—pancreatic cancer	0.00179	0.00505	CcSEcCtD
Vilazodone—Decreased appetite—Sunitinib—pancreatic cancer	0.00176	0.00499	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00175	0.00495	CcSEcCtD
Vilazodone—Fatigue—Sunitinib—pancreatic cancer	0.00175	0.00494	CcSEcCtD
Vilazodone—Asthenia—Tamoxifen—pancreatic cancer	0.0017	0.0048	CcSEcCtD
Vilazodone—Convulsion—Fluorouracil—pancreatic cancer	0.0017	0.0048	CcSEcCtD
Vilazodone—Arthralgia—Gemcitabine—pancreatic cancer	0.0017	0.0048	CcSEcCtD
Vilazodone—Increased appetite—Epirubicin—pancreatic cancer	0.00169	0.00477	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00169	0.00477	CcSEcCtD
Vilazodone—Asthenia—Erlotinib—pancreatic cancer	0.00168	0.00475	CcSEcCtD
Vilazodone—Nervous system disorder—Irinotecan—pancreatic cancer	0.00164	0.00463	CcSEcCtD
Vilazodone—Diarrhoea—Tamoxifen—pancreatic cancer	0.00162	0.00458	CcSEcCtD
Vilazodone—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00162	0.00457	CcSEcCtD
Vilazodone—Diarrhoea—Erlotinib—pancreatic cancer	0.0016	0.00453	CcSEcCtD
Vilazodone—Connective tissue disorder—Docetaxel—pancreatic cancer	0.0016	0.00452	CcSEcCtD
Vilazodone—Nervous system disorder—Gemcitabine—pancreatic cancer	0.0016	0.00451	CcSEcCtD
Vilazodone—Hyponatraemia—Epirubicin—pancreatic cancer	0.00159	0.0045	CcSEcCtD
Vilazodone—Skin disorder—Gemcitabine—pancreatic cancer	0.00158	0.00447	CcSEcCtD
Vilazodone—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00157	0.00445	CcSEcCtD
Vilazodone—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00157	0.00444	CcSEcCtD
Vilazodone—Dizziness—Tamoxifen—pancreatic cancer	0.00157	0.00443	CcSEcCtD
Vilazodone—Increased appetite—Doxorubicin—pancreatic cancer	0.00156	0.00441	CcSEcCtD
Vilazodone—Migraine—Epirubicin—pancreatic cancer	0.00156	0.00441	CcSEcCtD
Vilazodone—Dizziness—Erlotinib—pancreatic cancer	0.00155	0.00438	CcSEcCtD
Vilazodone—Eye disorder—Docetaxel—pancreatic cancer	0.00152	0.0043	CcSEcCtD
Vilazodone—Insomnia—Irinotecan—pancreatic cancer	0.00151	0.00427	CcSEcCtD
Vilazodone—Cardiac disorder—Docetaxel—pancreatic cancer	0.00151	0.00427	CcSEcCtD
Vilazodone—Vomiting—Tamoxifen—pancreatic cancer	0.00151	0.00426	CcSEcCtD
Vilazodone—Paraesthesia—Irinotecan—pancreatic cancer	0.0015	0.00424	CcSEcCtD
Vilazodone—Vomiting—Erlotinib—pancreatic cancer	0.00149	0.00421	CcSEcCtD
Vilazodone—Somnolence—Irinotecan—pancreatic cancer	0.00149	0.0042	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00148	0.00419	CcSEcCtD
Vilazodone—Hyponatraemia—Doxorubicin—pancreatic cancer	0.00147	0.00416	CcSEcCtD
Vilazodone—Insomnia—Gemcitabine—pancreatic cancer	0.00147	0.00416	CcSEcCtD
Vilazodone—Dyspepsia—Irinotecan—pancreatic cancer	0.00147	0.00416	CcSEcCtD
Vilazodone—Paraesthesia—Gemcitabine—pancreatic cancer	0.00146	0.00413	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00146	0.00412	CcSEcCtD
Vilazodone—Asthenia—Sunitinib—pancreatic cancer	0.00146	0.00411	CcSEcCtD
Vilazodone—Decreased appetite—Irinotecan—pancreatic cancer	0.00145	0.00411	CcSEcCtD
Vilazodone—Insomnia—Fluorouracil—pancreatic cancer	0.00145	0.00409	CcSEcCtD
Vilazodone—Somnolence—Gemcitabine—pancreatic cancer	0.00145	0.00409	CcSEcCtD
Vilazodone—Migraine—Doxorubicin—pancreatic cancer	0.00144	0.00408	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00144	0.00408	CcSEcCtD
Vilazodone—Fatigue—Irinotecan—pancreatic cancer	0.00144	0.00407	CcSEcCtD
Vilazodone—Paraesthesia—Fluorouracil—pancreatic cancer	0.00144	0.00406	CcSEcCtD
Vilazodone—Breast disorder—Epirubicin—pancreatic cancer	0.00143	0.00405	CcSEcCtD
Vilazodone—Mental disorder—Docetaxel—pancreatic cancer	0.00142	0.00403	CcSEcCtD
Vilazodone—Somnolence—Fluorouracil—pancreatic cancer	0.00142	0.00402	CcSEcCtD
Vilazodone—Malnutrition—Docetaxel—pancreatic cancer	0.00142	0.004	CcSEcCtD
Vilazodone—Decreased appetite—Gemcitabine—pancreatic cancer	0.00142	0.004	CcSEcCtD
Vilazodone—Dyspepsia—Fluorouracil—pancreatic cancer	0.00141	0.00398	CcSEcCtD
Vilazodone—Nausea—Tamoxifen—pancreatic cancer	0.00141	0.00398	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00141	0.00397	CcSEcCtD
Vilazodone—Fatigue—Gemcitabine—pancreatic cancer	0.0014	0.00397	CcSEcCtD
Vilazodone—Nausea—Erlotinib—pancreatic cancer	0.00139	0.00393	CcSEcCtD
Vilazodone—Decreased appetite—Fluorouracil—pancreatic cancer	0.00139	0.00393	CcSEcCtD
Vilazodone—Diarrhoea—Sunitinib—pancreatic cancer	0.00139	0.00392	CcSEcCtD
Vilazodone—Dysgeusia—Docetaxel—pancreatic cancer	0.00139	0.00392	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00138	0.00391	CcSEcCtD
Vilazodone—Feeling abnormal—Irinotecan—pancreatic cancer	0.00138	0.00389	CcSEcCtD
Vilazodone—Dizziness—Sunitinib—pancreatic cancer	0.00134	0.00379	CcSEcCtD
Vilazodone—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00134	0.00379	CcSEcCtD
Vilazodone—Breast disorder—Doxorubicin—pancreatic cancer	0.00133	0.00375	CcSEcCtD
Vilazodone—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00132	0.00373	CcSEcCtD
Vilazodone—Vomiting—Sunitinib—pancreatic cancer	0.00129	0.00365	CcSEcCtD
Vilazodone—Pollakiuria—Epirubicin—pancreatic cancer	0.00127	0.00358	CcSEcCtD
Vilazodone—Palpitations—Docetaxel—pancreatic cancer	0.00125	0.00354	CcSEcCtD
Vilazodone—Convulsion—Docetaxel—pancreatic cancer	0.00123	0.00347	CcSEcCtD
Vilazodone—Arthralgia—Docetaxel—pancreatic cancer	0.00121	0.00341	CcSEcCtD
Vilazodone—Nausea—Sunitinib—pancreatic cancer	0.00121	0.00341	CcSEcCtD
Vilazodone—Asthenia—Irinotecan—pancreatic cancer	0.0012	0.00339	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.0012	0.00338	CcSEcCtD
Vilazodone—Dry mouth—Docetaxel—pancreatic cancer	0.00118	0.00333	CcSEcCtD
Vilazodone—Pollakiuria—Doxorubicin—pancreatic cancer	0.00117	0.00331	CcSEcCtD
Vilazodone—Asthenia—Gemcitabine—pancreatic cancer	0.00117	0.0033	CcSEcCtD
Vilazodone—Diarrhoea—Irinotecan—pancreatic cancer	0.00114	0.00323	CcSEcCtD
Vilazodone—Nervous system disorder—Docetaxel—pancreatic cancer	0.00113	0.0032	CcSEcCtD
Vilazodone—Skin disorder—Docetaxel—pancreatic cancer	0.00112	0.00317	CcSEcCtD
Vilazodone—Diarrhoea—Gemcitabine—pancreatic cancer	0.00111	0.00315	CcSEcCtD
Vilazodone—Dizziness—Irinotecan—pancreatic cancer	0.00111	0.00312	CcSEcCtD
Vilazodone—Diarrhoea—Fluorouracil—pancreatic cancer	0.0011	0.0031	CcSEcCtD
Vilazodone—Connective tissue disorder—Epirubicin—pancreatic cancer	0.00108	0.00305	CcSEcCtD
Vilazodone—Vomiting—Irinotecan—pancreatic cancer	0.00106	0.003	CcSEcCtD
Vilazodone—Dizziness—Fluorouracil—pancreatic cancer	0.00106	0.00299	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00105	0.00298	CcSEcCtD
Vilazodone—Insomnia—Docetaxel—pancreatic cancer	0.00104	0.00295	CcSEcCtD
Vilazodone—Paraesthesia—Docetaxel—pancreatic cancer	0.00104	0.00293	CcSEcCtD
Vilazodone—Vomiting—Gemcitabine—pancreatic cancer	0.00104	0.00293	CcSEcCtD
Vilazodone—Somnolence—Docetaxel—pancreatic cancer	0.00103	0.0029	CcSEcCtD
Vilazodone—Eye disorder—Epirubicin—pancreatic cancer	0.00102	0.0029	CcSEcCtD
Vilazodone—Cardiac disorder—Epirubicin—pancreatic cancer	0.00102	0.00288	CcSEcCtD
Vilazodone—Vomiting—Fluorouracil—pancreatic cancer	0.00102	0.00288	CcSEcCtD
Vilazodone—Dyspepsia—Docetaxel—pancreatic cancer	0.00102	0.00287	CcSEcCtD
Vilazodone—Decreased appetite—Docetaxel—pancreatic cancer	0.001	0.00284	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000997	0.00282	CcSEcCtD
Vilazodone—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000997	0.00282	CcSEcCtD
Vilazodone—Fatigue—Docetaxel—pancreatic cancer	0.000996	0.00282	CcSEcCtD
Vilazodone—Nausea—Irinotecan—pancreatic cancer	0.000993	0.00281	CcSEcCtD
Vilazodone—Nausea—Gemcitabine—pancreatic cancer	0.000967	0.00273	CcSEcCtD
Vilazodone—Mental disorder—Epirubicin—pancreatic cancer	0.000961	0.00272	CcSEcCtD
Vilazodone—Malnutrition—Epirubicin—pancreatic cancer	0.000955	0.0027	CcSEcCtD
Vilazodone—Feeling abnormal—Docetaxel—pancreatic cancer	0.000952	0.00269	CcSEcCtD
Vilazodone—Nausea—Fluorouracil—pancreatic cancer	0.000951	0.00269	CcSEcCtD
Vilazodone—Eye disorder—Doxorubicin—pancreatic cancer	0.000948	0.00268	CcSEcCtD
Vilazodone—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000942	0.00266	CcSEcCtD
Vilazodone—Flatulence—Epirubicin—pancreatic cancer	0.000941	0.00266	CcSEcCtD
Vilazodone—Dysgeusia—Epirubicin—pancreatic cancer	0.000935	0.00264	CcSEcCtD
Vilazodone—Nervousness—Epirubicin—pancreatic cancer	0.000927	0.00262	CcSEcCtD
Vilazodone—Vision blurred—Epirubicin—pancreatic cancer	0.0009	0.00254	CcSEcCtD
Vilazodone—Mental disorder—Doxorubicin—pancreatic cancer	0.000889	0.00251	CcSEcCtD
Vilazodone—Malnutrition—Doxorubicin—pancreatic cancer	0.000883	0.0025	CcSEcCtD
Vilazodone—Agitation—Epirubicin—pancreatic cancer	0.000877	0.00248	CcSEcCtD
Vilazodone—Flatulence—Doxorubicin—pancreatic cancer	0.000871	0.00246	CcSEcCtD
Vilazodone—Dysgeusia—Doxorubicin—pancreatic cancer	0.000865	0.00245	CcSEcCtD
Vilazodone—Nervousness—Doxorubicin—pancreatic cancer	0.000858	0.00243	CcSEcCtD
Vilazodone—Palpitations—Epirubicin—pancreatic cancer	0.000844	0.00238	CcSEcCtD
Vilazodone—Vision blurred—Doxorubicin—pancreatic cancer	0.000833	0.00235	CcSEcCtD
Vilazodone—Asthenia—Docetaxel—pancreatic cancer	0.000829	0.00234	CcSEcCtD
Vilazodone—Convulsion—Epirubicin—pancreatic cancer	0.000827	0.00234	CcSEcCtD
Vilazodone—Arthralgia—Epirubicin—pancreatic cancer	0.000813	0.0023	CcSEcCtD
Vilazodone—Agitation—Doxorubicin—pancreatic cancer	0.000812	0.00229	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000807	0.00228	CcSEcCtD
Vilazodone—Dry mouth—Epirubicin—pancreatic cancer	0.000795	0.00225	CcSEcCtD
Vilazodone—Diarrhoea—Docetaxel—pancreatic cancer	0.00079	0.00223	CcSEcCtD
Vilazodone—Palpitations—Doxorubicin—pancreatic cancer	0.000781	0.00221	CcSEcCtD
Vilazodone—Convulsion—Doxorubicin—pancreatic cancer	0.000765	0.00216	CcSEcCtD
Vilazodone—Nervous system disorder—Epirubicin—pancreatic cancer	0.000764	0.00216	CcSEcCtD
Vilazodone—Dizziness—Docetaxel—pancreatic cancer	0.000764	0.00216	CcSEcCtD
Vilazodone—Skin disorder—Epirubicin—pancreatic cancer	0.000757	0.00214	CcSEcCtD
Vilazodone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000753	0.00213	CcSEcCtD
Vilazodone—Arthralgia—Doxorubicin—pancreatic cancer	0.000752	0.00213	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000747	0.00211	CcSEcCtD
Vilazodone—Dry mouth—Doxorubicin—pancreatic cancer	0.000736	0.00208	CcSEcCtD
Vilazodone—Vomiting—Docetaxel—pancreatic cancer	0.000735	0.00208	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.00071	0.00201	CcSEcCtD
Vilazodone—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000707	0.002	CcSEcCtD
Vilazodone—Insomnia—Epirubicin—pancreatic cancer	0.000705	0.00199	CcSEcCtD
Vilazodone—Skin disorder—Doxorubicin—pancreatic cancer	0.0007	0.00198	CcSEcCtD
Vilazodone—Paraesthesia—Epirubicin—pancreatic cancer	0.0007	0.00198	CcSEcCtD
Vilazodone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000697	0.00197	CcSEcCtD
Vilazodone—Somnolence—Epirubicin—pancreatic cancer	0.000693	0.00196	CcSEcCtD
Vilazodone—Nausea—Docetaxel—pancreatic cancer	0.000686	0.00194	CcSEcCtD
Vilazodone—Dyspepsia—Epirubicin—pancreatic cancer	0.000686	0.00194	CcSEcCtD
Vilazodone—Decreased appetite—Epirubicin—pancreatic cancer	0.000677	0.00191	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000673	0.0019	CcSEcCtD
Vilazodone—Fatigue—Epirubicin—pancreatic cancer	0.000672	0.0019	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000657	0.00186	CcSEcCtD
Vilazodone—Insomnia—Doxorubicin—pancreatic cancer	0.000652	0.00184	CcSEcCtD
Vilazodone—Paraesthesia—Doxorubicin—pancreatic cancer	0.000647	0.00183	CcSEcCtD
Vilazodone—Feeling abnormal—Epirubicin—pancreatic cancer	0.000642	0.00181	CcSEcCtD
Vilazodone—Somnolence—Doxorubicin—pancreatic cancer	0.000641	0.00181	CcSEcCtD
Vilazodone—Dyspepsia—Doxorubicin—pancreatic cancer	0.000635	0.00179	CcSEcCtD
Vilazodone—Decreased appetite—Doxorubicin—pancreatic cancer	0.000627	0.00177	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000622	0.00176	CcSEcCtD
Vilazodone—Fatigue—Doxorubicin—pancreatic cancer	0.000622	0.00176	CcSEcCtD
Vilazodone—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000594	0.00168	CcSEcCtD
Vilazodone—Asthenia—Epirubicin—pancreatic cancer	0.000559	0.00158	CcSEcCtD
Vilazodone—Diarrhoea—Epirubicin—pancreatic cancer	0.000533	0.00151	CcSEcCtD
Vilazodone—Asthenia—Doxorubicin—pancreatic cancer	0.000517	0.00146	CcSEcCtD
Vilazodone—Dizziness—Epirubicin—pancreatic cancer	0.000515	0.00146	CcSEcCtD
Vilazodone—Vomiting—Epirubicin—pancreatic cancer	0.000495	0.0014	CcSEcCtD
Vilazodone—Diarrhoea—Doxorubicin—pancreatic cancer	0.000493	0.00139	CcSEcCtD
Vilazodone—Dizziness—Doxorubicin—pancreatic cancer	0.000477	0.00135	CcSEcCtD
Vilazodone—Nausea—Epirubicin—pancreatic cancer	0.000463	0.00131	CcSEcCtD
Vilazodone—Vomiting—Doxorubicin—pancreatic cancer	0.000458	0.0013	CcSEcCtD
Vilazodone—Nausea—Doxorubicin—pancreatic cancer	0.000428	0.00121	CcSEcCtD
Vilazodone—HTR1A—GPCR downstream signaling—PTHLH—pancreatic cancer	6.55e-05	0.00142	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PRLHR—pancreatic cancer	6.32e-05	0.00137	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCK—pancreatic cancer	6.3e-05	0.00137	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—SHH—pancreatic cancer	6.27e-05	0.00136	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IAPP—pancreatic cancer	6.2e-05	0.00134	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CNR2—pancreatic cancer	6.14e-05	0.00133	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—GLP1R—pancreatic cancer	6.14e-05	0.00133	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SSTR3—pancreatic cancer	6.12e-05	0.00133	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—DTX1—pancreatic cancer	6.12e-05	0.00133	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—PTEN—pancreatic cancer	6.1e-05	0.00132	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCKAR—pancreatic cancer	6.04e-05	0.00131	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—IAPP—pancreatic cancer	5.99e-05	0.0013	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—SST—pancreatic cancer	5.99e-05	0.0013	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CXCL8—pancreatic cancer	5.99e-05	0.0013	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PTHLH—pancreatic cancer	5.95e-05	0.00129	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PTCH1—pancreatic cancer	5.95e-05	0.00129	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ZNRF3—pancreatic cancer	5.94e-05	0.00129	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ACVR1B—pancreatic cancer	5.94e-05	0.00129	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SSTR1—pancreatic cancer	5.86e-05	0.00127	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PPY—pancreatic cancer	5.75e-05	0.00125	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PTHLH—pancreatic cancer	5.75e-05	0.00125	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SSTR2—pancreatic cancer	5.64e-05	0.00122	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CNR1—pancreatic cancer	5.53e-05	0.0012	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—SHH—pancreatic cancer	5.51e-05	0.00119	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCKBR—pancreatic cancer	5.45e-05	0.00118	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IAPP—pancreatic cancer	5.44e-05	0.00118	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—SST—pancreatic cancer	5.44e-05	0.00118	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	5.42e-05	0.00118	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SSTR3—pancreatic cancer	5.37e-05	0.00116	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—DTX1—pancreatic cancer	5.37e-05	0.00116	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CD44—pancreatic cancer	5.35e-05	0.00116	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—GCG—pancreatic cancer	5.34e-05	0.00116	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—SST—pancreatic cancer	5.26e-05	0.00114	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PTHLH—pancreatic cancer	5.22e-05	0.00113	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PTCH1—pancreatic cancer	5.22e-05	0.00113	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SSTR1—pancreatic cancer	5.15e-05	0.00112	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GCG—pancreatic cancer	5.13e-05	0.00111	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—DTX4—pancreatic cancer	5.13e-05	0.00111	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GLI1—pancreatic cancer	5.13e-05	0.00111	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AGTR1—pancreatic cancer	5.09e-05	0.0011	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PPY—pancreatic cancer	5.05e-05	0.00109	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CNR1—pancreatic cancer	5.02e-05	0.00109	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NRP1—pancreatic cancer	4.99e-05	0.00108	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PPP2R5B—pancreatic cancer	4.99e-05	0.00108	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SSTR2—pancreatic cancer	4.96e-05	0.00107	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CNR1—pancreatic cancer	4.85e-05	0.00105	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—GCG—pancreatic cancer	4.85e-05	0.00105	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—STK11—pancreatic cancer	4.83e-05	0.00105	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HEY2—pancreatic cancer	4.8e-05	0.00104	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCKBR—pancreatic cancer	4.79e-05	0.00104	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—SST—pancreatic cancer	4.78e-05	0.00103	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	4.76e-05	0.00103	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GAST—pancreatic cancer	4.69e-05	0.00102	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—GCG—pancreatic cancer	4.69e-05	0.00102	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AGTR1—pancreatic cancer	4.62e-05	0.001	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GLI1—pancreatic cancer	4.5e-05	0.000975	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—DTX4—pancreatic cancer	4.5e-05	0.000975	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AGTR1—pancreatic cancer	4.47e-05	0.000969	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SCT—pancreatic cancer	4.44e-05	0.000963	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HEY1—pancreatic cancer	4.44e-05	0.000963	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CNR1—pancreatic cancer	4.41e-05	0.000955	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NRP1—pancreatic cancer	4.38e-05	0.000949	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PPP2R5B—pancreatic cancer	4.38e-05	0.000949	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—GCG—pancreatic cancer	4.26e-05	0.000922	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCK—pancreatic cancer	4.24e-05	0.000919	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HEY2—pancreatic cancer	4.21e-05	0.000913	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—TP53—pancreatic cancer	4.16e-05	0.000902	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—TYMS—pancreatic cancer	4.15e-05	0.0009	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PRSS1—pancreatic cancer	4.14e-05	0.000898	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CNR2—pancreatic cancer	4.13e-05	0.000895	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GLP1R—pancreatic cancer	4.13e-05	0.000895	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCL8—pancreatic cancer	4.13e-05	0.000895	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GAST—pancreatic cancer	4.12e-05	0.000892	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCKAR—pancreatic cancer	4.06e-05	0.000881	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AGTR1—pancreatic cancer	4.06e-05	0.00088	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JAG2—pancreatic cancer	3.94e-05	0.000854	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SCT—pancreatic cancer	3.9e-05	0.000846	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HEY1—pancreatic cancer	3.9e-05	0.000846	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MEN1—pancreatic cancer	3.88e-05	0.000842	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCK—pancreatic cancer	3.72e-05	0.000807	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SHH—pancreatic cancer	3.71e-05	0.000803	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOTCH4—pancreatic cancer	3.68e-05	0.000798	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IAPP—pancreatic cancer	3.66e-05	0.000793	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CNR2—pancreatic cancer	3.63e-05	0.000786	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GLP1R—pancreatic cancer	3.63e-05	0.000786	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCL8—pancreatic cancer	3.63e-05	0.000786	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ARG2—pancreatic cancer	3.59e-05	0.000778	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCKAR—pancreatic cancer	3.57e-05	0.000773	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTCH1—pancreatic cancer	3.51e-05	0.000761	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTHLH—pancreatic cancer	3.51e-05	0.000761	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JAG2—pancreatic cancer	3.46e-05	0.00075	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MEN1—pancreatic cancer	3.41e-05	0.000739	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—APOE—pancreatic cancer	3.38e-05	0.000732	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SHH—pancreatic cancer	3.25e-05	0.000705	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH4—pancreatic cancer	3.23e-05	0.000701	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IAPP—pancreatic cancer	3.21e-05	0.000696	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SST—pancreatic cancer	3.21e-05	0.000696	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CG—pancreatic cancer	3.17e-05	0.000687	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JAG1—pancreatic cancer	3.14e-05	0.000681	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TYMP—pancreatic cancer	3.14e-05	0.00068	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOTCH3—pancreatic cancer	3.13e-05	0.000679	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTHLH—pancreatic cancer	3.08e-05	0.000668	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTCH1—pancreatic cancer	3.08e-05	0.000668	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CG—pancreatic cancer	3.05e-05	0.00066	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CNR1—pancreatic cancer	2.97e-05	0.000643	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PPARG—pancreatic cancer	2.94e-05	0.000637	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CG—pancreatic cancer	2.88e-05	0.000624	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GCG—pancreatic cancer	2.86e-05	0.000621	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SST—pancreatic cancer	2.82e-05	0.000611	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.79e-05	0.000604	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CG—pancreatic cancer	2.78e-05	0.000603	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JAG1—pancreatic cancer	2.76e-05	0.000598	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH3—pancreatic cancer	2.75e-05	0.000596	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AGTR1—pancreatic cancer	2.73e-05	0.000592	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PRSS1—pancreatic cancer	2.71e-05	0.000587	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—STK11—pancreatic cancer	2.69e-05	0.000583	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CD—pancreatic cancer	2.68e-05	0.00058	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CNR1—pancreatic cancer	2.6e-05	0.000564	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GLP1R—pancreatic cancer	2.53e-05	0.000548	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CD—pancreatic cancer	2.53e-05	0.000548	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CG—pancreatic cancer	2.53e-05	0.000548	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GCG—pancreatic cancer	2.51e-05	0.000545	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—DPYD—pancreatic cancer	2.49e-05	0.00054	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.45e-05	0.00053	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.43e-05	0.000526	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AGTR1—pancreatic cancer	2.4e-05	0.00052	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STK11—pancreatic cancer	2.36e-05	0.000512	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	2.36e-05	0.000512	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SMAD4—pancreatic cancer	2.36e-05	0.000511	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ARG2—pancreatic cancer	2.35e-05	0.000509	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CB—pancreatic cancer	2.33e-05	0.000506	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL8—pancreatic cancer	2.33e-05	0.000506	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS2—pancreatic cancer	2.31e-05	0.000501	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HES1—pancreatic cancer	2.3e-05	0.000499	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CD—pancreatic cancer	2.22e-05	0.000481	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CB—pancreatic cancer	2.21e-05	0.000478	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.13e-05	0.000462	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL8—pancreatic cancer	2.12e-05	0.000459	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SMAD4—pancreatic cancer	2.07e-05	0.000449	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.05e-05	0.000445	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL8—pancreatic cancer	2.05e-05	0.000444	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HES1—pancreatic cancer	2.02e-05	0.000438	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TERT—pancreatic cancer	2.02e-05	0.000437	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTEN—pancreatic cancer	2.02e-05	0.000437	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CB—pancreatic cancer	1.94e-05	0.00042	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HIF1A—pancreatic cancer	1.93e-05	0.000418	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TSC2—pancreatic cancer	1.92e-05	0.000417	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOE—pancreatic cancer	1.88e-05	0.000408	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL8—pancreatic cancer	1.86e-05	0.000403	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KDR—pancreatic cancer	1.85e-05	0.0004	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CD44—pancreatic cancer	1.83e-05	0.000396	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TERT—pancreatic cancer	1.77e-05	0.000384	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NFKBIA—pancreatic cancer	1.76e-05	0.00038	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GCG—pancreatic cancer	1.75e-05	0.00038	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOTCH1—pancreatic cancer	1.74e-05	0.000377	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CG—pancreatic cancer	1.7e-05	0.000368	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—NRAS—pancreatic cancer	1.7e-05	0.000368	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HIF1A—pancreatic cancer	1.69e-05	0.000367	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TSC2—pancreatic cancer	1.69e-05	0.000366	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGF—pancreatic cancer	1.68e-05	0.000364	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.65e-05	0.000359	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOE—pancreatic cancer	1.65e-05	0.000358	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—STK11—pancreatic cancer	1.65e-05	0.000357	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.63e-05	0.000353	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KDR—pancreatic cancer	1.62e-05	0.000351	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	1.55e-05	0.000336	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.54e-05	0.000335	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NFKBIA—pancreatic cancer	1.54e-05	0.000334	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH1—pancreatic cancer	1.53e-05	0.000331	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	1.49e-05	0.000324	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CG—pancreatic cancer	1.49e-05	0.000323	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—NRAS—pancreatic cancer	1.49e-05	0.000323	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.48e-05	0.000321	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGF—pancreatic cancer	1.48e-05	0.00032	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	1.46e-05	0.000317	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CA—pancreatic cancer	1.42e-05	0.000308	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.42e-05	0.000307	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EGFR—pancreatic cancer	1.36e-05	0.000295	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.34e-05	0.000291	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	1.31e-05	0.000284	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.3e-05	0.000282	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.3e-05	0.000282	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	1.28e-05	0.000278	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	1.25e-05	0.000271	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	1.24e-05	0.00027	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	1.21e-05	0.000262	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	1.2e-05	0.00026	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CD44—pancreatic cancer	1.2e-05	0.000259	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	1.18e-05	0.000256	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	1.17e-05	0.000253	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—AKT1—pancreatic cancer	1.16e-05	0.000252	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.15e-05	0.00025	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOE—pancreatic cancer	1.15e-05	0.00025	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GCG—pancreatic cancer	1.15e-05	0.000249	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	1.14e-05	0.000248	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	1.13e-05	0.000245	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	1.13e-05	0.000244	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	1.1e-05	0.000238	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	1.1e-05	0.000238	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	1.09e-05	0.000237	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—STK11—pancreatic cancer	1.08e-05	0.000234	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	1.06e-05	0.00023	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CASP3—pancreatic cancer	1.05e-05	0.000228	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SRC—pancreatic cancer	1.04e-05	0.000226	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.04e-05	0.000226	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCND1—pancreatic cancer	1.02e-05	0.000222	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	1.02e-05	0.00022	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	1.01e-05	0.00022	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	1.01e-05	0.000218	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPARG—pancreatic cancer	1e-05	0.000218	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	1e-05	0.000218	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—pancreatic cancer	9.94e-06	0.000215	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTEN—pancreatic cancer	9.88e-06	0.000214	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	9.64e-06	0.000209	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—pancreatic cancer	9.35e-06	0.000203	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	9.33e-06	0.000202	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TYMS—pancreatic cancer	9.28e-06	0.000201	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SRC—pancreatic cancer	9.17e-06	0.000199	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	9.15e-06	0.000198	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	9.15e-06	0.000198	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	8.93e-06	0.000193	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STAT3—pancreatic cancer	8.84e-06	0.000192	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NRAS—pancreatic cancer	8.82e-06	0.000191	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	8.64e-06	0.000187	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—pancreatic cancer	8.21e-06	0.000178	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	8.19e-06	0.000178	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGFR—pancreatic cancer	8.03e-06	0.000174	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	7.98e-06	0.000173	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	7.94e-06	0.000172	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—pancreatic cancer	7.91e-06	0.000171	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TP53—pancreatic cancer	7.68e-06	0.000166	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KRAS—pancreatic cancer	7.59e-06	0.000164	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOE—pancreatic cancer	7.54e-06	0.000163	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	7.35e-06	0.000159	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	6.97e-06	0.000151	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTEN—pancreatic cancer	6.89e-06	0.000149	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	6.81e-06	0.000148	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TP53—pancreatic cancer	6.74e-06	0.000146	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARG—pancreatic cancer	6.57e-06	0.000142	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	6.49e-06	0.000141	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HRAS—pancreatic cancer	6.45e-06	0.00014	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	5.98e-06	0.00013	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKT1—pancreatic cancer	5.7e-06	0.000123	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	5.22e-06	0.000113	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—pancreatic cancer	5.17e-06	0.000112	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	4.86e-06	0.000105	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTEN—pancreatic cancer	4.51e-06	9.77e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AKT1—pancreatic cancer	3.97e-06	8.61e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	3.18e-06	6.89e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AKT1—pancreatic cancer	2.6e-06	5.63e-05	CbGpPWpGaD
